Research & Development

New Edition of NSF’s Health Sciences Journal Now Live

This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.

Sanofi to buy biopharmaceutical firm Principia Biopharma for $3.68bn

French drugmaker Sanofi has agreed to acquire late-stage biopharmaceutical company Principia Biopharma for an aggregate equity value of around $3.68bn.

UNION therapeutics to acquire licence for Covid-19 technologies developed by TFF Pharmaceuticals

UNION therapeutics announced the completion of an agreement with TFF Pharmaceuticals (TFF) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.

GeneCentric, Janssen collaborate to study genomic drug response biomarkers for NMIBC

GeneCentric Therapeutics has announced a research collaboration with Janssen Research & Development on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).

Bayer to buy UK biotech company KaNDy Therapeutics

Bayer has agreed to acquire UK-based clinical-stage biotech company KaNDy Therapeutics for an upfront consideration of $425m.

Ligand Pharmaceuticals to buy Pfenex for up to $516m

Ligand Pharmaceuticals has agreed to acquire development and licencing biotechnology company Pfenex in a deal valued at around $516m.

Seismic Bio partners with Twist Bioscience for discovery and optimisation of antibodies

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, an immuno-oncology company focused on bispecific antibody development, today announced a partnership for the discovery and optimization of antibodies to high-value immuno-oncology targets.

Pfizer says Covid-19 vaccine may be needed regularly

Pfizer is considering a long-term commercial strategy for its Covid-19 vaccine, anticipating that the novel coronavirus could endure and a one-time vaccine dose may not be enough.

Nura Bio launches to discover and develop neuroprotective drug

Nura Bio, a biopharma company created to discover and develop life-changing neuroprotective drugs, announced its official launch.